|Bid||1.0600 x 1200|
|Ask||1.2800 x 900|
|Day's range||1.1700 - 1.2450|
|52-week range||0.4600 - 3.3500|
|Beta (5Y monthly)||2.09|
|PE ratio (TTM)||N/A|
|Earnings date||31 Oct 2022 - 04 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||6.07|
It is doubtless a positive to see that the Infinity Pharmaceuticals, Inc. ( NASDAQ:INFI ) share price has gained some...
CAMBRIDGE, Mass., August 31, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that the Company will present and conduct 1-on-1 meetings with investors at the 2022 Wells Fargo Healthcare Conference and H.C. Wainwright 24th Annual Global Investment Conference.
Every investor in Infinity Pharmaceuticals, Inc. ( NASDAQ:INFI ) should be aware of the most powerful shareholder...